Teva Pharmaceutical Industries (TEVA)

TEVA REPORTS THIRD QUARTER 2007 RESULTS

Jerusalem, Israel, October 30, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced its financial results for the third quarter ended September 30, 2007.

TEVA REPORTS THIRD QUARTER 2007 RESULTS

Jerusalem, Israel, October 30, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced its financial results for the third quarter ended September 30, 2007.

TEVA REPORTS SECOND QUARTER 2007 RESULTS

Jerusalem, Israel, August 1, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today announced its financial results for the second quarter ended June 30, 2007.

TEVA REPORTS FIRST QUARTER 2007 RESULTS

●       Net Sales Increased 24% to $2,080 Million.

●       Reported Net Income of $342 Million and Earning per Share of $0.42, up 20% and 14% respectively from Adjusted Net Income and EPS for the first quarter 2006.

●       Cash Flow from Operations of $499 Million.

Jerusalem, Israel, May 2, 2007 - Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) today reported results for the quarter ended March 31, 2007.

Quarterly Net Sales reached $2,080 million, an increase of 24% over the comparable quarter of 2006, with sales benefiting from both the inclusion of a full quarter of sales of Ivax businesses, as compared with two months in the comparable quarter of 2006, and from the strengthening of various currencies against the US Dollar, mainly European currencies.  

Net Income for the first quarter of 2007 was $342 million and fully diluted EPS reached $0.42. The 2006 GAAP figures include a write-off of $1.3 billion, after tax, relating primarily to the Ivax acquisition and consisting of in-process R&D and an inventory step up.  Net Income and EPS for the first quarter of 2007 increased 20% and 14%, respectively, compared to the figures for the first quarter of 2006 after adjustment for these items.  These 2006 adjusted data are considered non-GAAP financial measures.  Teva believes that excluding these items facilitates investors` understanding of the trends in the Company`s underlying business. Currencies had a minimal effect on Net Income.

Shlomo Yanai, Teva`s President and Chief Executive Officer, commented on today`s results: "Teva is off to a great start in 2007. Strong demand for our generics products across all our geographies, along with record-breaking quarterly sales of Copaxone®, and the continued rapid growth of our respiratory franchise, drove our results in the first quarter even higher than we had anticipated."

Mr. Yanai added: "Teva`s achievements in the first quarter provide a perfect demonstration of this company`s unique capabilities, and how we are able to leverage our position as the industry leader to succeed in a highly competitive environment and to maximize the many opportunities that lie ahead."

North American pharmaceutical sales (including Copaxone^®) accounted for 51% of the Company`s total sales and reached $1,071 million in the quarter, compared to $881 million in the first quarter of 2006, an increase of 22%. Sales in the first quarter benefited from strong sales of oxycodone and bupropion XL, and increased sales of Teva's branded respiratory products and innovative products (Copaxone^® and Azilect^®).